SG11201704962WA - Amino acid and peptide conjugates and uses thereof - Google Patents

Amino acid and peptide conjugates and uses thereof

Info

Publication number
SG11201704962WA
SG11201704962WA SG11201704962WA SG11201704962WA SG11201704962WA SG 11201704962W A SG11201704962W A SG 11201704962WA SG 11201704962W A SG11201704962W A SG 11201704962WA SG 11201704962W A SG11201704962W A SG 11201704962WA SG 11201704962W A SG11201704962W A SG 11201704962WA
Authority
SG
Singapore
Prior art keywords
amino acid
peptide conjugates
conjugates
peptide
amino
Prior art date
Application number
SG11201704962WA
Inventor
Margaret Anne Brimble
Peter Roderick Dunbar
Geoffrey Martyn Williams
Daniel Verdon
Original Assignee
Margaret Anne Brimble
Peter Roderick Dunbar
Geoffrey Martyn Williams
Daniel Verdon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Margaret Anne Brimble, Peter Roderick Dunbar, Geoffrey Martyn Williams, Daniel Verdon filed Critical Margaret Anne Brimble
Publication of SG11201704962WA publication Critical patent/SG11201704962WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201704962WA 2014-12-23 2015-12-22 Amino acid and peptide conjugates and uses thereof SG11201704962WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462096106P 2014-12-23 2014-12-23
PCT/IB2015/059901 WO2016103192A1 (en) 2014-12-23 2015-12-22 Amino acid and peptide conjugates and uses thereof

Publications (1)

Publication Number Publication Date
SG11201704962WA true SG11201704962WA (en) 2017-07-28

Family

ID=56149361

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704962WA SG11201704962WA (en) 2014-12-23 2015-12-22 Amino acid and peptide conjugates and uses thereof

Country Status (13)

Country Link
US (2) US10253062B2 (en)
EP (1) EP3237374A4 (en)
JP (2) JP2018505152A (en)
KR (1) KR20170094449A (en)
CN (1) CN107250103A (en)
AU (2) AU2015370479B2 (en)
BR (1) BR112017013574A2 (en)
CA (1) CA2971677A1 (en)
IL (1) IL252902A0 (en)
MX (1) MX2017008406A (en)
RU (1) RU2017126206A (en)
SG (1) SG11201704962WA (en)
WO (1) WO2016103192A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107141410B (en) * 2010-05-25 2022-12-09 辛德弗雷克斯公司 Polymer-conjugated MetAP2 inhibitors and methods of treatment using the same
AU2014250983B2 (en) 2013-04-10 2019-04-11 Syndevrx, Inc. MetAP2 inhibitors and methods of treating obesity
CN105555756B (en) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 Amino acid conjugate and peptide conjugate and conjugation methods
BR112017013574A2 (en) 2014-12-23 2018-03-06 Verdon Daniel amino acid and peptide conjugates and uses thereof
JP7161404B2 (en) 2016-02-26 2022-10-26 オークランド ユニサービシーズ リミティド Amino acid and peptide conjugates and conjugation methods
NL2018803B1 (en) * 2017-04-27 2018-11-05 Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc Adjuvant compounds

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0014815A3 (en) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptide derivatives, process for their preparation and intermediates, and pharmaceutical compositions containing one of these compounds
US4939240A (en) 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US6024964A (en) 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US6074650A (en) 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
DE3813821A1 (en) 1988-04-22 1989-11-02 Hoechst Ag SYNTHETIC VACCINE AGAINST MOUTH AND CLAUS DISEASE AND METHOD FOR THEIR PRODUCTION
US4743543A (en) 1985-09-09 1988-05-10 Coulter Corporation Method for enhancing and/or accelerating immunoassay detection of human carcinoma tumor associated antigen in a pathology sample
US4921790A (en) 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5053489A (en) 1988-01-29 1991-10-01 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4914021A (en) 1988-03-04 1990-04-03 New England Deaconess Hospital Corporation Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US4921789A (en) 1988-04-20 1990-05-01 New England Deaconess Hospital Corporation Marker for colorectal carcinoma and methods of detecting the same
JPH02172946A (en) 1988-12-26 1990-07-04 Shinetsu Sakusan Vinyl Kk Production of alkenyl carboxylate
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
CA2131528C (en) 1992-03-05 2004-07-13 Philip E. Thorpe Methods and compositions for targeting the vasculature of solid tumors
WO1994013806A1 (en) 1992-12-11 1994-06-23 The Dow Chemical Company Multivalent single chain antibodies
CA2154266A1 (en) 1993-02-05 1994-08-18 John F. Codington Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
US6310180B1 (en) 1993-06-21 2001-10-30 Vanderbilt University Method for synthesis of proteins
DE4331011A1 (en) 1993-09-13 1995-03-16 Bayer Ag C-branched oligomers that bind nucleic acids for therapy and diagnostics
AUPM446594A0 (en) * 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
JPH08248579A (en) 1995-03-14 1996-09-27 Mitsubishi Paper Mills Ltd Silver halide photographic sensitive material and its processing method
US5994294A (en) 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
AUPO007396A0 (en) * 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
US6251603B1 (en) 1996-10-03 2001-06-26 Ludwig Institute For Cancer Research Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
DE69837273T2 (en) 1997-10-08 2008-01-31 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services HUMAN CANCER ANTIBODY NY ESO-1 / CAG-3 AND GENEAN CODING THEREFOR
US6602505B2 (en) * 1998-04-30 2003-08-05 University Of Southern California Viral chimeras comprised of CAEV and HIV-1 genetic elements
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
JP4698027B2 (en) 1999-02-01 2011-06-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 Immune adjuvant compounds
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
AU776058B2 (en) 1999-11-15 2004-08-26 Chancellor, Masters And Scholars Of The University Of Oxford, The NY-ESO-1 nonapeptide derivatives, and uses thereof
EP2311950A1 (en) 2000-01-28 2011-04-20 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
WO2002000623A2 (en) 2000-06-26 2002-01-03 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
US6506875B1 (en) 2000-09-26 2003-01-14 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-C molecules and uses thereof
GB0030067D0 (en) 2000-12-11 2001-01-24 Univ Bristol Therapeutic agent
EP1229043A1 (en) 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
AU2002353485B2 (en) 2001-12-04 2009-01-15 Ben Gurion University Of The Negev Research And Development Authority Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
NZ537579A (en) 2002-06-10 2006-10-27 Vaccinex Inc C35 peptide epitopes and their analogs
GB0214528D0 (en) * 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
DK1543039T3 (en) 2002-08-12 2011-10-31 Queensland Inst Med Res Novel immunogenic lipopeptides comprising T helper and B cell epitopes
KR101151368B1 (en) 2002-08-12 2012-06-08 더 카운실 오브 더 퀸스랜드 인스티튜트 오브 메디칼 리서어치 - novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte ctl epitopes
TW200416043A (en) 2002-11-07 2004-09-01 Queensland Inst Med Res Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
US20080139464A1 (en) 2003-05-30 2008-06-12 Ludwig Institute Of Cancer Research Isolated Ny-Eso-1 Peptides Which Bind To Hla Class II Molecules And Uses Thereof
WO2005012270A2 (en) 2003-07-29 2005-02-10 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic amines, amides, and sulfur-containing compounds and methods of making and using the same
EP1666056A1 (en) 2004-12-06 2006-06-07 Bestewil Holding B.V. Cancer vaccine vesicles
US20080233143A1 (en) 2005-02-07 2008-09-25 Lipotek Pty Ltd. Adjuvanting Material
FR2881746B1 (en) * 2005-02-07 2007-04-13 Centre Nat Rech Scient CD4 + EPITOPES OF TYTE I AND II LATENCY ANTIGENS OF THE EPSTEIN-BARR VIRUS FIT TO BE RECOGNIZED BY THE MAJORITY OF INDIVIDUALS OF THE CAUCASIAN POPULATION AND THEIR APPLICATIONS
BRPI0607605A2 (en) 2005-02-08 2009-09-15 Queensland Inst Med Res immunogenic molecules
GB0507003D0 (en) 2005-04-06 2005-05-11 Molmed Spa Therapeutic
KR20080030564A (en) 2005-05-12 2008-04-04 태피스트리 파마슈티컬스 인코퍼레이티드 Molecular constructs suitable for targeted conjugates
CN100548377C (en) 2005-07-18 2009-10-14 曾毅 The vaccine combination that contains the dendritic cell after modified
CA2620899A1 (en) 2005-10-12 2007-04-19 Biolipox Ab Benzoxazoles useful in the treatment of inflammation
JP4824389B2 (en) 2005-10-28 2011-11-30 株式会社医学生物学研究所 Cytotoxic T cell epitope peptide that specifically attacks Epstein-Barr virus infected cells and uses thereof
CA2632402A1 (en) 2005-12-06 2007-06-14 Savine Therapeutics Pty Ltd Treatment of epstein-barr virus-associated diseases
WO2007078879A2 (en) 2005-12-21 2007-07-12 Vaxinnate Corporation Lipopeptide compositions and methods of use thereof
FR2896162B1 (en) 2006-01-13 2008-02-15 Sanofi Pasteur Sa EMULSION OIL IN THERMOREVERSIBLE WATER
US20090123488A1 (en) 2006-08-14 2009-05-14 Thymon, Llc Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
US8309096B2 (en) 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
DK2118128T3 (en) 2007-01-15 2013-02-18 Glaxosmithkline Biolog Sa Fusion proteins comprising the tumor rejection antigens NY-ESO-1 and LAGE-1
EP2462947B1 (en) 2007-03-26 2019-03-13 Academisch Ziekenhuis Leiden h.o.d.n. LUMC PRAME derived peptides and immunogenic compositions comprising these
WO2008151197A2 (en) 2007-06-04 2008-12-11 The Regents Of The University Of California Tumor-derived endogenous toll-like receptor 4 ligands
EP2320882A4 (en) 2008-07-07 2014-12-31 Univ Melbourne A synthetic vaccine component
US20100266623A1 (en) 2008-07-07 2010-10-21 The University Of Melbourne Synthetic, self adjuvanting vaccines
CA2736187A1 (en) 2008-09-05 2010-03-11 Id Biomedical Corporation Of Quebec Novel compositions and adjuvants
US8436015B2 (en) 2008-09-15 2013-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2012523379A (en) 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン Immunogenic compositions and uses thereof
GB0917090D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
WO2011063233A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011063272A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
US20130045203A1 (en) 2010-03-02 2013-02-21 Emory University Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP
WO2011119628A2 (en) 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
US20130029358A1 (en) 2010-04-01 2013-01-31 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
WO2011156686A2 (en) 2010-06-11 2011-12-15 The Regents Of The University Of Colorado, A Body Corporate Method for synthesizing a cyclic multivalent peptide using a thiol-mediated reaction
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
ES2655535T3 (en) 2010-08-25 2018-02-20 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) A vaccine against the Epstein-Barr virus
EP2611905A4 (en) 2010-09-01 2014-02-12 Baylor College Medicine Ebv-specific cytotoxic t-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (npc)
BR112013005970A2 (en) 2010-09-14 2016-07-05 Council Scient Ind Res Synthetic immunogen, useful for generating lasting immunity and protection against pathogens.
SI2618835T1 (en) 2010-09-20 2017-10-30 Biontech Cell & Gene Therapies Gmbh Antigen-specific t cell receptors and t cell epitopes
AU2011305061B2 (en) 2010-09-22 2016-04-14 Ena Respiratory Pty Ltd Novel immunostimulatory method
WO2012069188A1 (en) 2010-11-24 2012-05-31 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V Continuous flow processes for photoconjugation of high-molecular chemical entities
US9187534B2 (en) 2011-03-11 2015-11-17 Universite De Geneve Multi-epitopic vaccine
DK2686020T3 (en) 2011-03-17 2017-05-01 Univ Birmingham REDIRECTED IMMUNTERY
EP2707356A4 (en) 2011-05-13 2014-10-15 Univ Nanyang Tech Method for modification of organic molecules
US20120328660A1 (en) 2011-06-03 2012-12-27 Tsuji Takemasa Immunogenic compositions useful in provoking an integrated response to tumor antigens
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
US10406248B2 (en) 2011-09-10 2019-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Molecular imaging of cancer cells in vivo
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
SG11201401177WA (en) 2011-10-06 2014-04-28 Immunovaccine Technologies Inc Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
US9056141B2 (en) 2012-05-31 2015-06-16 Synchem, Inc. Thiol-ene click chemistry for drug conjugates
US9861702B2 (en) 2012-10-22 2018-01-09 Wisconsin Alumni Research Foundation Lipid-conjugated rhamnose for immune system recruitment and oncotherapy
CA2893918C (en) 2012-12-06 2020-11-24 Callaghan Innovation Research Limited Conjugate compounds
CN105555756B (en) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 Amino acid conjugate and peptide conjugate and conjugation methods
BR112017013574A2 (en) 2014-12-23 2018-03-06 Verdon Daniel amino acid and peptide conjugates and uses thereof
JP7161404B2 (en) 2016-02-26 2022-10-26 オークランド ユニサービシーズ リミティド Amino acid and peptide conjugates and conjugation methods

Also Published As

Publication number Publication date
MX2017008406A (en) 2018-04-24
CA2971677A1 (en) 2016-06-30
RU2017126206A3 (en) 2019-04-22
EP3237374A4 (en) 2018-04-25
US20190256552A1 (en) 2019-08-22
US20180002373A1 (en) 2018-01-04
JP2018505152A (en) 2018-02-22
WO2016103192A1 (en) 2016-06-30
US10253062B2 (en) 2019-04-09
IL252902A0 (en) 2017-08-31
AU2020256429A1 (en) 2020-11-12
EP3237374A1 (en) 2017-11-01
CN107250103A (en) 2017-10-13
AU2015370479B2 (en) 2020-07-23
KR20170094449A (en) 2017-08-17
JP2021073199A (en) 2021-05-13
US11014960B2 (en) 2021-05-25
RU2017126206A (en) 2019-01-25
AU2015370479A1 (en) 2017-07-06
BR112017013574A2 (en) 2018-03-06

Similar Documents

Publication Publication Date Title
IL265796A (en) Compositions comprising pedf-derived short peptides and uses thereof
IL251571B (en) Lepidopteran-active cry1da1 amino acid sequence variant proteins
IL252902A0 (en) Amino acid and peptide conjugates and uses thereof
HK1254601A1 (en) Novel peptide
GB201400292D0 (en) Peptide dendrimers and agents
HK1248729A1 (en) Cytotoxic hexim1 peptides and uses thereof
EP3262061C0 (en) Peptides for facilitating secretion and uses thereof
IL287985A (en) Koc1-derived peptide and vaccine including same
EP3199543A4 (en) Novel peptide and use thereof
GB2543713B (en) Polymeric proteins and uses thereof
GB2546439B (en) Ezrin-derived peptides and pharmaceutical compositions thereof
HK1255012A1 (en) Amino acid-containing composition
IL251289B (en) Novel peptide derivatives and uses thereof
PT3438118T (en) Peptide derivative and use thereof
IL250215A0 (en) Cdca1-derived peptide and vaccine containing same
GB201612150D0 (en) Modified peptide
EP3325499A4 (en) Novel peptide and use thereof
IL250235A0 (en) Urlc10-derived peptide and vaccine containing same
SG11201610918RA (en) Peptides and uses thereof
GB201401673D0 (en) Esculentin-2CHa peptide and analogues thereof
GB201617925D0 (en) Proteins and uses
GB201620022D0 (en) Novel peptide